There are no verified statistics about deaths occurring in hotels, and only a few cases have been described in the literature. A recent case induced us to conduct a systematic search for deaths in hotels in the autopsy reports of the Institute of Legal Medicine in Giessen for the period from 1968 to 2009. This search yielded 22 evaluable cases in which persons had been found dead or had died in hotels. Data evaluated in the study were sex and age of the deceased, reason for the stay in the hotel and cause of death. Among the deaths, 18 were males and 4 females and the average age was 41 and 40 years respectively. 6 of the male guests had died from a natural and 10 from a non-natural cause. In the remaining two cases, the cause of death could not be determined, but as there was no evidence that another party had been involved, the cases were not further investigated. Of the 4 female guests, 3 had died of a natural cause; in one case, the cause of death remained unclear even after morphological and toxicological investigations. Surprisingly, a third of the men were found to be temporarily living in hotels due to social circumstances. This was not true for any of the women. Our retrospective analysis is based on a comparatively small number of deaths in what were mostly hotels in small to medium-sized towns. Interestingly, the gender ratio of 18:4 for deceased men and women was significantly higher than the usual gender ratio of 2:1 found for forensic autopsies. To be able to draw further conclusions, a greater number of cases would have to be analysed, for example by recruiting additional case files from other institutes of legal medicine. This would also open up the option of investigating possible regional variations.
Download full-text PDF |
Source |
---|
Lancet Planet Health
December 2024
Institute of Environmental Medicine, Karolinska Institutet, Stockholm, Sweden; Department of Cardiology, Danderyd University Hospital, Danderyd, Sweden.
Background: In 2019, the Global Burden of Diseases, Injuries, and Risk Factors Study attributed 0·98 million deaths to ambient air pollution in India based on potentially inappropriate exposure-response functions from countries with low air pollution levels. Instead, using data from India, we investigated long-term exposure to PM and all-cause mortality with a causal inference method.
Methods: We collected national counts of annual mortality from 2009 to 2019 from the Civil Registration System at the district level to calculate annual district-level mortality rate as our main outcome and obtained annual PM concentrations from a high-resolution spatiotemporal model.
Blood
December 2024
Department of Hematology & Medical Oncology, Winship Cancer Institute of Emory University, United States.
Early intervention of smoldering multiple myeloma (SMM) may delay progression to multiple myeloma. Here, we present the final analysis of the phase 2 CENTAURUS study (NCT02316106). In total, 123 patients with intermediate/high-risk SMM were randomized to intravenous daratumumab 16 mg/kg following a Long intense (n = 41), Intermediate (n = 41), or Short intense (n = 41) dosing schedule.
View Article and Find Full Text PDFN Engl J Med
December 2024
From Alexandra General Hospital, National and Kapodistrian University of Athens, Athens (M.A.D.); Levine Cancer Institute, Atrium Health Wake Forest University School of Medicine, Charlotte, NC (P.M.V.); Oslo Myeloma Center, Department of Hematology, Oslo University Hospital, Oslo (F.S.); Tel-Aviv Sourasky (Ichilov) Medical Center and Tel Aviv University, Tel Aviv, Israel (Y.C.C.); Clínica Medica São Germano, São Paulo (V.H.); Cross Cancer Institute, University of Alberta, Edmonton, Canada (I. Sandhu); Kent and Canterbury Hospital, Canterbury, United Kingdom (J.L.); Perth Blood Institute, Murdoch University, Perth, WA, Australia (R.I.B.); Japanese Red Cross Medical Center, Tokyo (K.S.); Ogaki Municipal Hospital, Ogaki City, Japan (H.K.); Albert Schweitzer Hospital, Dordrecht, the Netherlands (M.-D.L.); Ankara University, Ankara, Turkey (M.B.); Washington University School of Medicine, St. Louis (K.S.-G.); Institut Català d'Oncologia and Institut Josep Carreras, Hospital Germans Trias i Pujol, Barcelona (A.O.); South Pest Central Hospital, National Institute for Hematology and Infectious Diseases, Budapest, Hungary (G.M.); Hospital Alemán, Buenos Aires (G.G.); Jessa Hospital, Hasselt, Belgium (K.T.); Charles University and General Hospital, Prague, Czech Republic (I. Spicka); Rigshospitalet, University of Copenhagen, Copenhagen (A.K.M.); SSD Clinical Trials in Oncol-ematologia e Mieloma Multiplo, AOU Città della Salute e della Scienza di Torino, Turin, Italy (S.B.); Medical Unit Hematology, Karolinska University Hospital, Stockholm (K.U.); Institute of Hematology and Transfusion Medicine, Warsaw, Poland (B.P.); Knight Cancer Institute, Oregon Health and Science University, Portland (E.M.); University of Washington and Fred Hutchinson Cancer Center, Seattle (A.J.C.); University Hospital Hôtel-Dieu, Nantes, France (P.M.); University Hospital of Salamanca, IBSAL, and Cancer Research Center, IBMCC, Salamanca, Spain (M.-V.M.); GMMG Study Group at University Hospital Heidelberg, Internal Medicine V, Heidelberg, Germany (H.G.); Genmab US, Plainsboro, NJ (T.A.); Janssen Research and Development, Shanghai, China (L.S., L.L.); Janssen Scientific Affairs, Horsham, PA (A.C.); Janssen Research and Development, Raritan, NJ (E.G.K., R.M.D.); Janssen Research and Development, Beerse, Belgium (E.R.); Janssen Research and Development, Spring House, PA (R.C.); and Mayo Clinic, Rochester, MN (S.V.R.).
Background: Daratumumab, an anti-CD38 monoclonal antibody, has been approved for the treatment of multiple myeloma. Data are needed regarding the use of daratumumab for high-risk smoldering multiple myeloma, a precursor disease of active multiple myeloma for which no treatments have been approved.
Methods: In this phase 3 trial, we randomly assigned patients with high-risk smoldering multiple myeloma to receive either subcutaneous daratumumab monotherapy or active monitoring.
Clin Toxicol (Phila)
December 2024
Unité Médico-judiciaire, Hôpital Hôtel-Dieu, APHP, Paris, France.
Hypertension
December 2024
Direction des maladies non transmissibles, Santé publique France, Saint-Maurice, France (C.G., A.G., M.J.T., V.O.).
Background: Hypertension is the most common chronic disease and a major modifiable risk factor for cardio-cerebrovascular and renal diseases. This study estimated the national burden of hypertension, defined as systolic blood pressure ≥140 mm Hg, on morbidity and mortality in 2021 in France.
Methods: For all diseases causally associated with hypertension (cardiovascular diseases, chronic kidney diseases, and dementia), the number and proportion of cases attributable to hypertension in adults aged ≥35 years were estimated using population attributable fractions.
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!